Search clinical trials for: BI 836826

Total 1237 results

Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Crohn Disease

Belgium, Germany, Austria, Netherlands, Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. (ROBIN)

Diabetic Retinopathy

United States, Spain, Italy, United Kingdom, Austria, Greece, Norway, Portugal
Boehringer Ingelheim

Completed

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Non-alcoholic Fatty Liver Disease

United States, Spain, United Kingdom, Belgium, Canada, Germany, Netherlands, France, Ireland
Bezmialem Vakif University

Unknown

Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation

Intrauterine Growth Restriction | Fetal Surveillance

Turkey
Boehringer Ingelheim

Completed

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Idiopathic Pulmonary Fibrosis

Spain, United Kingdom, Italy, Belgium, Germany, Netherlands, Finland, Denmark
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Denmark, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan
Boehringer Ingelheim

Completed

Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo

Healthy

Germany
Boehringer Ingelheim

Completed

This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

Healthy

Korea, Republic of
Linnea Polgreen

Completed

Text Messages and Blood Pressure Control

Hypertension

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Terminated

Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

Asthma | Rhinitis, Allergic, Perennial

Korea, Republic of
Boehringer Ingelheim

Completed

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Neoplasms

Spain, Korea, Republic of, Belgium, Taiwan, United Kingdom, Austria, France, Netherlands, Ireland, Sweden
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Hypertension, Portal

Spain, Denmark, United Kingdom, Singapore, Germany, Italy, Austria, Canada, Croatia, China, Taiwan, Netherlands, Belgium, United States, Korea, Republic of, Japan, Argentina, France, Switzerland, Portugal, Israel, Romania
Evangelismos Hospital
Sotiria General Hospital; Elpis General Hospital; Evgenidion Hospital

Completed

Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery

Morbid Obesity | Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | Hypoxemia | Hypoxemic Respiratory Failure | Atelectasis | Pulmonary Infection
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Scleroderma Research Foundation, Inc.
Sanofi; Boehringer Ingelheim

Not yet recruiting

Platform Clinical Study for Conquering Scleroderma (CONQUEST)

Scleroderma | Interstitial Lung Disease Due to Systemic Disease

United States
University of Michigan Rogel Cancer Center

Not yet recruiting

Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors

Body Image | Adolescent Cancer | Young Adult Cancer

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Lung Diseases, Interstitial

United States, Spain, China, United Kingdom, Canada, Norway, Korea, Republic of, Belgium, Australia, Germany, Denmark, Singapore, Taiwan, Thailand, Italy, Japan, Finland, Turkey, Croatia, Switzerland, France, Serbia, Netherlands, Mala... and more
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE™-1)

Obesity

United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Finland, Germany, Canada, Netherlands, New Zealand, Sweden, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Spain, China, Canada, Norway, Korea, Republic of, Taiwan, Belgium, Australia, Germany, Denmark, Singapore, Thailand, Italy, Japan, United Kingdom, Switzerland, Croatia, France, Netherlands, Malaysia, New Zealand, Arge... and more
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Alkahest, Inc.

Completed

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Neoplasms

United States, Taiwan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

Healthy
Duke University

Completed

Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging

Lung Cancer | Metastatic Cancer in the Lungs

United States
Boehringer Ingelheim

Completed

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

HIV Infections

United States, Puerto Rico
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Schizophrenia

United States, Taiwan, Germany, Japan, Canada
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine

3

Subscribe